Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 4/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25365287 | 0.81 | IRAK4 (0.34) | LIPELPLLIPG | |
| SCHEMBL1104989 | 0.77 | LPL (0.36) | LIPELPLLIPG | |
| SCHEMBL23104189 | 0.77 | PI4KA (0.37) | CYP1A2 | |
| SCHEMBL30203974 | 0.75 | L3MBTL1 (0.33) | LPLLIPG | |
| SCHEMBL781799 | 0.75 | L3MBTL1 (0.33) | LPLLIPG | |
| SCHEMBL9938454 | 0.73 | IRAK4 (0.39) | LPLLIPG | |
| SCHEMBL285259 | 0.72 | CYP17A1 (0.35) | CYP17A1CYP1A2 | |
| SCHEMBL5956817 | 0.72 | NCF1 (0.39) | CYP17A1CYP1A2 | |
| SCHEMBL21820851 | 0.71 | LPL (0.33) | LIPELPLLIPG | |
| SCHEMBL26043533 | 0.71 | IRAK4 (0.39) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3651768-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11739098-B2 | Substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3710440-B1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230098244-A1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-30 | — | — | US | disclosed |
| US-11434233-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-06 | — | — | US | disclosed |
| US-11420973-B2 | Amide substituted indole compounds useful as TLR inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3728221-B1 | AMIDE SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11306092-B2 | Amino indole compounds useful as TLR inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3728218-B1 | AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210253593-A1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-19 | — | — | US | disclosed |
| US-8173635-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173635-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173635-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2427464-A1 | PYRAZOLOPYRIDINES | Vertex Pharmaceuticals Incorporated (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129668-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-11 | — | — | WO | disclosed |
| EP-2215089-A1 | [1H- PYRAZOLO [3, 4-B]PYRIDINE-4-YL]-PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA | Vertex Pharmaceuticals Incorporated (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090291937-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
| US-20090291937-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
| US-20090291937-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
| WO-2009073300-A1 | [1H- PYRAZOLO [3, 4-B] PYRIDINE-4-YL] -PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291937-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | LIPE 2774/4885CYP17A1 2828/4885CYP1A2 3257/4885 |
| US-11306092-B2 | Amino indole compounds useful as TLR inhibitors | TLR7, TLR1, TLR9 | LIPE 4196/4885CYP17A1 4418/4885CYP1A2 3992/4885 |
| US-11420973-B2 | Amide substituted indole compounds useful as TLR inhibitors | TLR9, TLR1, TLR7 | LIPE 3497/4885CYP17A1 4698/4885CYP1A2 3365/4885 |
| US-11434233-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | LIPE 4670/4885CYP17A1 3492/4885CYP1A2 4172/4885 |
| US-20230098244-A1 | SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, HTR7 | LIPE 2430/4885CYP17A1 2221/4885CYP1A2 1447/4885 |
| US-20210253593-A1 | SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, HTR7 | LIPE 2430/4885CYP17A1 2221/4885CYP1A2 1447/4885 |
| US-11739098-B2 | Substituted indole compounds | TLR7, TLR1, HTR7 | LIPE 2430/4885CYP17A1 2221/4885CYP1A2 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.